Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit. The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs. Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way. They expect significant manufacturing increases to occur, starting in the back half of the year. CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.” Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter. |
Xi Stresses Implementing Guiding Principles of Key Party Congress in Armed ForcesSubsidies not reason for Chinese EVs competitive advantage: ministerXi Focus: Xi Addresses CIIE, Calls for Joint Efforts for Bright Future of Openness, ProsperityXi Stresses Studying, Understanding, Implementing Guiding Principles of Key Party CongressMan of the People58 killed by 2 weeks of floods in TanzaniaProfile: Xi Jinping Leads China on New Journey(CPC Congress) CPC Elects New Central Committee, New Central Commission for Discipline InspectionChina's used vehicle sales up in first 2 monthsXi Jinping Leads CPC Leadership in Meeting the Press